The burden of severe depression: a review of diagnostic challenges and treatment alternatives
- PMID:16870212
- DOI: 10.1016/j.jpsychires.2006.05.008
The burden of severe depression: a review of diagnostic challenges and treatment alternatives
Abstract
Among the factors making recognition of severe depression problematic for clinicians are the heterogeneous nature of the condition, lack of standardized definitions, and concomitant comorbidities that confound differential diagnosis of symptoms. The spectrum of severity in depressive disorders is extraordinarily broad, and severity assessment is comprised of several metrics including symptom intensity, diagnostic subtypes, suicidality risk, and hospitalization status. The overall diagnosis is achieved through consideration of symptom types and severities together with the degree of functional impairment as assessed by the psychiatric interview. It is likely that no single fundamental neurobiological defect underlies severe depression. The chronicity and heterogeneity of this disorder lead to frequent clinic visits and a longer course of treatment; therefore, successful approaches may require an arsenal of treatments with numerous mechanisms of action. The categories of drugs used to treat severe depression are detailed herein, as are several non-pharmacologic options including a number of experimental treatments. Pharmacotherapies include tricyclic antidepressants, selective serotonin reuptake inhibitors, atypical antidepressants such as serotonin-norepinephrine reuptake inhibitors and monoamine oxidase inhibitors, and combination and augmentation therapies. Drugs within each class are not equivalent, and efficacy may vary with symptom severity. Patient adherence makes tolerability another critical consideration in antidepressant choice. The role of non-pharmacological treatments such as electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation remain active avenues of investigation. Improved knowledge and treatment approaches for severe depression are necessary to facilitate remission, the ideal treatment goal.
Similar articles
- Treatment resistant depression--advances in somatic therapies.Kennedy SH, Giacobbe P.Kennedy SH, et al.Ann Clin Psychiatry. 2007 Oct-Dec;19(4):279-87. doi: 10.1080/10401230701675222.Ann Clin Psychiatry. 2007.PMID:18058285Review.
- Clinical management of the depressed geriatric patient: current therapeutic options.Mendels J.Mendels J.Am J Med. 1993 May 24;94(5A):13S-18S.Am J Med. 1993.PMID:8503475Review.
- Antidepressant agents for the treatment of chronic pain and depression.Jann MW, Slade JH.Jann MW, et al.Pharmacotherapy. 2007 Nov;27(11):1571-87. doi: 10.1592/phco.27.11.1571.Pharmacotherapy. 2007.PMID:17963465Review.
- Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes.Papolos D, Mattis S, Golshan S, Molay F.Papolos D, et al.J Affect Disord. 2009 Nov;118(1-3):28-38. doi: 10.1016/j.jad.2009.06.016. Epub 2009 Jul 23.J Affect Disord. 2009.PMID:19631388
- Treatment-resistant depression: critique of current approaches.Wijeratne C, Sachdev P.Wijeratne C, et al.Aust N Z J Psychiatry. 2008 Sep;42(9):751-62. doi: 10.1080/00048670802277206.Aust N Z J Psychiatry. 2008.PMID:18696279Review.
Cited by
- The severity of psychiatric disorders.Zimmerman M, Morgan TA, Stanton K.Zimmerman M, et al.World Psychiatry. 2018 Oct;17(3):258-275. doi: 10.1002/wps.20569.World Psychiatry. 2018.PMID:30192110Free PMC article.
- Association between continuity of care and subsequent hospitalization and mortality in patients with mood disorders: Results from the Korea National Health Insurance cohort.Kim W, Jang SY, Lee TH, Lee JE, Park EC.Kim W, et al.PLoS One. 2018 Nov 19;13(11):e0207740. doi: 10.1371/journal.pone.0207740. eCollection 2018.PLoS One. 2018.PMID:30452465Free PMC article.
- MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective.Ortega MA, Alvarez-Mon MA, García-Montero C, Fraile-Martinez O, Lahera G, Monserrat J, Muñoz-Merida L, Mora F, Rodríguez-Jiménez R, Fernandez-Rojo S, Quintero J, Álvarez-Mon M.Ortega MA, et al.Biomedicines. 2021 Nov 10;9(11):1659. doi: 10.3390/biomedicines9111659.Biomedicines. 2021.PMID:34829888Free PMC article.Review.
- Identification of diagnostic markers for major depressive disorder by cross-validation of data from whole blood samples.Wang H, Zhang M, Xie Q, Yu J, Qi Y, Yue Q.Wang H, et al.PeerJ. 2019 Jun 21;7:e7171. doi: 10.7717/peerj.7171. eCollection 2019.PeerJ. 2019.PMID:31275757Free PMC article.
- Integrated Analysis of Methylomic and Transcriptomic Data to Identify Potential Diagnostic Biomarkers for Major Depressive Disorder.Xie Y, Xiao L, Chen L, Zheng Y, Zhang C, Wang G.Xie Y, et al.Genes (Basel). 2021 Jan 27;12(2):178. doi: 10.3390/genes12020178.Genes (Basel). 2021.PMID:33513891Free PMC article.
Publication types
MeSH terms
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical